Human Pathology
Volume 37, Issue 3 , Pages 298-311 , March 2006

Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells

  • Xing Cui, MD, PhD

      Affiliations

    • Environmental Health Sciences Division, National Institute for Environmental Studies, Tsukuba, Ibaraki 305-8506, Japan
    • Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata City 951-8510, Japan
    • Corresponding Author InformationCorresponding author. Environmental Health Sciences Division, National Institute for Environmental Studies, Tsukuba, Ibaraki 305-8506, Japan.
    • ,
  • Toshifumi Wakai, MD, PhD

      Affiliations

    • Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata City 951-8510, Japan
    • ,
  • Yoshio Shirai, MD, PhD

      Affiliations

    • Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata City 951-8510, Japan
    • ,
  • Naoyuki Yokoyama, MD, PhD

      Affiliations

    • Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata City 951-8510, Japan
    • ,
  • Katsuyoshi Hatakeyama, MD, PhD

      Affiliations

    • Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata City 951-8510, Japan
    • ,
  • Seishiro Hirano, PhD

      Affiliations

    • Environmental Health Sciences Division, National Institute for Environmental Studies, Tsukuba, Ibaraki 305-8506, Japan

Received 6 July 2005 ,Revised 27 October 2005 ,Accepted 27 October 2005.

References 

  1. Sherr CJ. Principles of tumor suppression. Cell. 2004;116:235–246
  2. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4:143–153
  3. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042–2054
  4. Tycko B. Epigenetic gene silencing in cancer. J Clin Invest. 2000;11:401–407
  5. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol. 2003;163:1371–1378
  6. Jin M, Piao Z, Kim NG, et al. p16 is a major inactivation target in hepatocellular carcinoma. Cancer. 2000;89:60–68
  7. Schagdarsurengin U, Wilkens L, Steinemann D, et al. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene. 2003;22:1866–1871
  8. Zhong S, Yeo W, Tang MW, Wong N, Lai PB, Johnson PJ. Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus–associated hepatocellular carcinomas. Clin Cancer Res. 2003;9:3376–3382
  9. Roncalli M, Bianchi P, Bruni B, et al. Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology. 2002;36:427–432
  10. Wei Y, Van Nhieu JT, Prigent S, Srivatanakul P, Tiollais P, Buendia MA. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features. Hepatology. 2002;36:692–701
  11. Yang B, Guo M, Herman JG, Clark DP. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol. 2003;163:1101–1107
  12. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res. 1998;58:4515–4518
  13. Bakker J, Lin X, Nelson WG. Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells. J Biol Chem. 2002;277:22573–22580
  14. Rhee I, Bachman KE, Park BH, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002;416:552–556
  15. Robert MF, Morin S, Beaulieu N, et al. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet. 2003;33:61–65
  16. Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21:5483–5495
  17. Shao W, Fanelli M, Ferrara FF, et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst. 1998;90:124–133
  18. Miller WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002;62:3893–3903
  19. Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci U S A. 1997;94:10907–10912
  20. Sciandrello G, Caradonna F, Mauro M, Barbata G. Arsenic-induced DNA hypomethylation affects chromosomal instability in mammalian cells. Carcinogenesis. 2004;25:413–417
  21. Detich N, Hamm S, Just G, Knox JD, Szyf M. The methyl donor S-adenosylmethionine inhibits active demethylation of DNA: a candidate novel mechanism for the pharmacological effects of S-adenosylmethionine. J Biol Chem. 2003;278:20812–20820
  22. Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB. Controlled synthesis of HBsAg in a differentiated human liver carcinoma–derived cell line. Nature. 1979;282:615–616
  23. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 1982;42:3858–3863
  24. Greene FL, Page DL, Fleming ID, et al. In: American Joint Committee on Cancer Staging Manual. 6th ed.. New York: Springer-Verlag; 2002;p. 131–138
  25. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821–9826
  26. Cui X, Shirai Y, Wakai T, Yokoyama N, Hirano S, Hatakeyama K. Aberrant expression of pRb and p16(INK4), alone or in combination, indicates poor outcome after resection in patients with colorectal carcinoma. Hum Pathol. 2004;35:1189–1195
  27. Boyes J, Bird A. Repression of genes by DNA methylation depends on CpG density and promoter strength evidence for involvement of a methyl-CpG binding protein. EMBO J. 1992;11:327–333
  28. Hsieh CL. Dependence of transcriptional repression on CpG methylation density. Mol Cell Biol. 1994;14:5487–5494
  29. Liu LH, Xiao WH, Liu WW. Effect of 5-aza-2′-deoxycytidine on the p16 tumor suppressor gene in hepatocellular carcinoma cell line HepG2. J World Gastroenterol. 2001;7:131–135
  30. Fukai K, Yokosuka O, Chiba T, et al. Hepatocyte growth factor activator inhibitor 2/placental bikunin (HAI-2/PB) gene is frequently hypermethylated in human hepatocellular carcinoma. Cancer Res. 2003;63:8674–8679
  31. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354–3360
  32. Cui X, Kobayashi Y, Hayakawa T, Hirano S. Arsenic speciation in bile and urine following oral and intravenous exposure to inorganic and organic arsenics in rats. Toxicol Sci. 2004;82:478–487
  33. Hayakawa T, Kobayashi Y, Cui X, Hirano S. A new metabolic pathway of arsenite: arsenic-glutathione complexes are substrates for human arsenic methyltransferase Cyt19. Arch Toxicol. 2005;79:183–191
  34. Saito Y, Kanai Y, Nakagawa T, et al. Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer. 2003;11:527–532
  35. Momparler RL, Cote S, Eliopoulos N. Pharmacological approach for optimization of the concentration schedule of 5-aza-2′-deoxycytidine (Decitabine) for the therapy of leukemia. Leukemia. 1997;11:175–180

☆ Grant Support: This study was supported in part by Grants-in-aid for Scientific Research (Young Scientists B, no. 14780433) from the Japan Society for the Promotion of Science (to Dr Cui).

PII: S0046-8177(05)00606-4

doi: 10.1016/j.humpath.2005.10.013

Human Pathology
Volume 37, Issue 3 , Pages 298-311 , March 2006

Article Tools

* Image Usage & Resolution